Process for Covid-19 vaccine clinical trials begins at NIMS Hyderabad

"Everything will be sent to ICMR, where data is analysed. We have already started the screening of individuals. We will first take audiovisual consent of the individual," the medical officer added

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
The clinical trials proposal was already placed before the NIMS hospital ethics committee.
Press Trust of India Hyderabad
2 min read Last Updated : Jul 07 2020 | 7:18 PM IST
The process of conducting clinical trials for Covaxin, a vaccine candidate for Covid-19, began on Tuesday at the Nizams Institute of Medical Sciences (NIMS) here, a top official of the state-run medical facility said.

"We will select healthy individuals and draw blood and send the blood samples to designated labs in New Delhi.

They will give the green signal. Then the medicine people will examine and the first shot of the vaccine will be given due observation," NIMS director Dr K Manohar told PTI.

The Indian Council of Medical Research (ICMR) has identified 12 clinical trial sites such as medical institutions and hospitals, including NIMS, and has asked their principal investigators to ensure that the subject enrolment is initiated no later than July 7.

"Everything will be sent to ICMR, where data is analysed. We have already started the screening of individuals. We will first take audiovisual consent of the individual," the medical officer added.

Asked about the total number of individuals required for the clinical trial, Manohar said at least 30 are needed.

The clinical trials proposal was already placed before the NIMS hospital ethics committee.

The Drug Controller General of India recently granted permission to initiate Phase I & II human clinical trials for Covid-19 Vaccine Covaxin- being developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccinehealthcare

Next Story